BMH BRÄUTIGAM advises the shareholders on the sale of Haupt Pharma AG to Aenova

BMH BRÄUTIGAM, jointly with Prange & Partner Rechtsanwälte Wirtschafsprüfer Steuerberater, advised the shareholders of Haupt Pharma AG on the sale of Haupt Pharma Group to Aenova Group.

The company, founded in 1937, generated in 2012 a turnover of EUR 282 mio with 2,000 employees and 9 premises, making it one of the biggest companies for pharmaceutical toll manufacturing and toll development in Europe. Due to the acquisition, Aenova Group will increase its turnover by 60 per cent to EUR 750 mio and its number of employees to over 4,000. The equity for the transaction will primarily be provided by funds managed by BC Partners. BC Partners, a leading private equity company, acquired Aenova Group in 2012 and has intensified the group´s growth since then. Otto Prange, chairman of Haupt Pharma AG’s supervisory board, will continue to hold an interest in Haupt Pharma AG as co-investor of Aenova Group. BMH BRÄUTIGAM advised Haupt Pharma in the last years on stock corporation law issues. BMH BRÄUTIGAM has also advised the buyout of the minority shareholder at the end of 2012 and works for other companies of the Prange Group, to which Haupt Pharma AG belongs.